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A b s T r A C T
Wilson’s disease (Wd) is a disorder of copper metabolism 
leading to copper accumulation in the liver and in 
extrahepatic organs, such as brain and cornea. We present a 
patient with liver disease who did not fulfil the biochemical 
criteria for Wd. Mutational analysis was necessary to make 
the diagnosis and show a new mutation. our case supports 
the use of mutation analysis in cases with unclear liver 
disease and suggests that the spectrum of Wd is broader 
than currently assumed. 
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i N T r o d U C T i o N
Wilson’s disease (WD) is a rare autosomal recessive 
disorder of copper metabolism. The ATP7B protein is an 
important transporter of copper and is responsible for 
WD; dysfunction can lead to copper accumulation in the 
liver and in extrahepatic organs, such as brain and cornea. 
This can lead to liver disease but also to (neuro)psychiatric 
disorders and Kayser-Fleischer (KF) rings around the 
iris. The diagnosis of WD is based on the results of 
several clinical and biochemical tests (decreased serum 
ceruloplasmin concentration, elevated 24-hour urinary 
copper excretion or elevated liver copper concentration). A 
liver biopsy with copper deposits is considered to be ‘the 
gold standard’ for the diagnosis.
WD is usually diagnosed in childhood and most physicians 
are aware of the association of the above-mentioned clinical 
findings with WD. However, in the absence of ‘typical’ 
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clinical findings, WD is a diagnosis that can be hard to 
make. We would like to present a patient in whom we were 
only able to make the diagnosis of WD at adult age aided 
by molecular testing of the WD gene, ATP7B.1,2
C A s E  r E P o r T
A 28-year-old woman visited our outpatient’s clinic because 
of cryptogenic liver disease. At the age of 10 years she 
presented with disturbed liver enzymes without signs 
of viral hepatitis, autoimmune hepatitis, toxic hepatitis 
or metabolic liver diseases such as alpha-1 antitrypsin 
deficiency or hereditary haemochromatosis. Biochemistry 
demonstrated a decreased ceruloplasmin (0.13 g/l, normal 
0.2 to 0.5 g/l), and mildly increased urinary copper 
excretion (2.31 umol/24 h, normal <1.5 umol/24 h). 
Repeated ophthalmological examination never showed 
Kayser-Fleischer rings. A liver biopsy at the age of 13 
years showed steatosis and fibrosis. Copper staining was 
negative, reason to reject a diagnosis of WD at that time. 
At reassessment 15 years later, WD was reconsidered. The 
transaminases were still elevated (alanine aminotransferase 
138 U/l; aspartate aminotransferase 63 (normal <45 U/l)). 
Serum copper was normal, most probably because the 
major copper binding protein in the plasma, ceruloplasmin, 
was only mildly decreased (0.17 g/l). In the absence of 
another explanation for the liver disease and in view of the 
decreased ceruloplasmin with increased urinary copper 
excretion of 2.9 umol/24 h we proceeded to perform 
mutation analysis of the ATP7B gene. Upon sequencing 
we detected compound heterozygosity for c.3207C>A 
(p.H1069Q) and c.2447+2T>A (figure 1, panel A). The 
p.H1069Q mutation is the most commonly detected 
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mutation in WD; the second mutation c.2447+2T>A is a 
novel frame-shift mutation. We analysed the c.2447+2T>A 
variant for potential effects on the splice site using the 
splice site prediction by neural network (SSPNN; http://
www.fruitfly.org/seq_tools/splice.html). The programme 
predicts the theoretical strength of donor and acceptor 
splice sites. The original splice site of intervening sequence 
9 (IVS9) reaches the maximum probability score of 1.00 
indicating that when the c.2447T>A variant is inserted in 
the sequence, the splice site is abolished. 
We proceeded to perform a new liver biopsy which 
was consistent with periportal hepatitis, ballooning of 
hepatocytes, steatosis and bridging fibrosis (Metavir 2); 
again copper staining was negative (figure 1, panel B-D) 
The Metavir score assesses liver fibrosis on a five-point 
scale (0 = no fibrosis, 1 = portal fibrosis without septa, 2 
= few septa, 3 = numerous septa without cirrhosis, 4 = 
cirrhosis). Given the positive molecular diagnosis of WD, 
we started her on chelating therapy with zinc sulphate 
(200 mg three times/day). 
d i s C U s s i o N
WD is characterised by a decreased biliary copper excretion 
and a defective incorporation of copper into ceroloplasmin, 
leading to copper accumulation in liver and brain. The 
prevalence is about 1 in 30,000. The range of clinical 
symptoms in Wilson’s disease is wide; hepatic disease 
can lead to elevated transaminases, chronic hepatitis, 
cirrhosis and fulminant liver failure. Brain involvement 
is associated with neurological symptoms such as tremor, 
chorea, parkinsonism, pseudobulbar symptoms, dystonia 
and seizures and even psychiatric disease. The archetypical 
figure 1. A) The sequence analysis of ATP7B gene on an electrospherogram, B-D) Liver biopsy specimen of a 
28-year-old patient with Wilson’s disease
A) The left insert shows the mutant sequence in the patient. There is a c .2447+2T>A mutation at the splice donor site of intron 9 that affects 
splicing pre-messenger-rNA from ATP7B.
b) Copper staining is absent (rhodanine staining) (10x). 
C) Elastic-van Giesons’s staining on a representative liver section compatible with bridging fibrosis (5x).1
d) Haematoxylin eosin staining, original magnification (20x): there is 1) periportal hepatitis with 2) ballooning of hepatocytes and 3) moderate 
steatosis.
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ocular symptoms are KF rings and cataract. In rare cases 
other organs such as heart (cardiomyopathy) can be 
involved.
There is not a single specific test for the diagnosis of WD; 
symptoms are often nonspecific. KF rings are often present, 
especially in patients with predominantly neurological 
disease (85 to 98%), in contrast to patients with 
predominantly liver disease where KF were detected in only 
52%.1,2 Quantitative copper concentration measurement 
remains the best biochemical evidence for WD, but due 
to a considerable sampling error, normal hepatic copper 
content does not exclude WD.3 Histochemical staining by 
rhodanine is not a substitute; less than 10% of confirmed 
cases had proteinaceous copper deposits in hepatocytes.4 
To simplify the difficult diagnosis a diagnostic scoring 
system for WD has been proposed recently. This score 
includes data on the presence of KF rings, neuropsychiatric 
symptoms, haemolytic anaemia, urine copper, quantitative 
liver copper, rhodanine staining, serum ceruloplamin and 
mutation analysis.5 Prior to mutational analysis our patient 
scored 2 points (decreased ceruloplasmin and increased 
urine copper excretion); after introduction of mutational 
analysis in the algorithm 4 additional points were gained: 
this made the diagnosis of WD ‘highly likely’. Although it 
aids in making the diagnosis, we need to emphasise that 
this scoring system has not been assessed prospectively. 
The gene that is defective in WD is ATP7B which encodes 
a transmembrane protein ATPase which functions as a 
copper-dependent P-type ATPase. The ATP7B transporter 
has synthetic and excretory roles, facilitating transport of 
copper into the trans-Golgi compartment, for incorporation 
into ceruloplasmin and into bile. When copper excess 
is present, the transporter adopts an excretory role by 
increasing biliary copper excretion. The ATP7B gene 
was cloned in 1993; since then more than 380 mutations 
have been reported in patients with WD from many 
different populations (http://www.medgen.med.ualberta.
ca/database.html). The p.H1069Q mutation is the most 
commonly detected mutation in WD, and has an allele 
frequency of up to 72% among WD patients. This mutation 
is seen in patients with late manifestations of WD and is 
associated with only a mildly disturbed copper metabolism. 
In compound heterozygotes, the phenotype of WD to a 
small extent depends on the type of mutation coinherited 
with p.H1069Q. Homozygosity for frameshift mutations 
in ATP7B is associated with severe disturbances of copper 
metabolism and presentation at young age. The effect of 
compound heterozygosity of a mild (p.H1069Q) and severe 
(c.2447+2T>A) mutation is less well established although 
these patients develop WD at a later stage than carriers of 
two severe mutations.6 
Our case history highlights several important aspects 
of WD. First, this case expands the clinical phenotype 
of Wilson’s disease, showing that advanced WD can be 
present without readily detectable tissue copper staining. 
This apparently contradicts the concept that readily 
detectable liver copper accumulation should be present 
to diagnose WD. Negative copper staining results may 
be explained by heterogeneous liver copper distribution 
(sampling error) and differences in sensitivity of rhodanine 
for free copper and copper binding proteins, but might also 
suggest that other, hitherto unknown, cofactors might be 
present in order to cause liver fibrosis. It also shows the 
importance of molecular testing in cases with equivocal 
biochemical results as this showed the presence of two 
pathogenic ATPB7 mutations consistent with WD. Lastly, 
the novel mutation adds to the mutational spectrum of 
WD.
Our data support the use of mutation analysis in cases 
with unclear liver disease with negative copper staining 
results and suggest that the spectrum of WD is broader 
than currently assumed. 
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